Houston, TX -- (SBWIRE) -- 03/22/2013 -- AnotherWinningTrade.com offers its daily alerts and market content newsletter to investors looking for the best information available! AnotherWinningTrade.com provides its subscribers with useful, timely information and exclusive alerts on penny stocks, mid cap stocks and large cap stocks with the potential to deliver gains of 100%-200% or more. We have the top alerts in the industry. To receive our FREE, comprehensive newsletter, visit AnotherWinningTrade.com.
Halozyme Therapeutics, Inc.(NASDAQ:HALO) jumped 15.28% and is trading at $6.07. Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix. The Company’s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology.
How Should Investors Trade HALO After The Solid Jump? Let’s Find Out Here
Diana Shipping Inc.(NYSE:DSX) is higher 5.94% and is trading at $10.17. Diana Shipping Inc. is a holding company. The Company is a global provider of shipping transportation services. It specialize in transporting dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes.
Is DSX Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here
FreeSeas Inc.(NASDAQ:FREE) soared 17.12% and is trading at $1.30. FreeSeas Inc. (FreeSeas) is a parent holding company of its ship-owning companies. The Company owns nine vessels, each of which is owned through a separate wholly owned subsidiary.
Is FREE Buy After The Recent Price Movement? Find Out Here
Cleveland BioLabs, Inc.(NASDAQ:CBLI) added 8.72% and is trading at $2.12. Cleveland BioLabs, Inc. is a clinical-stage biotechnology company with a focus on oncology drug development. The Company’s lead drug candidate CBLB502 is developed for dual indications under the United States Food & Drug Administration's (FDA's) Animal Efficacy Rule, commonly referred to as the Animal Rule, as a radiation countermeasure, and under the FDA's traditional drug approval pathway as an anti-cancer agent and an oncology supportive care therapy.
Is CBLI a Buy At The Current Market Price? Don’t Miss Out Our Special Coverage Here
Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.
Winning Media LLC
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)